Share

August 2016; 3 (4) ArticleOpen Access

Increased ratio of circulating neutrophils to monocytes in amyotrophic lateral sclerosis

Benjamin J. Murdock, Diane E. Bender, Samy R. Kashlan, Claudia Figueroa-Romero, Carey Backus, Brian C. Callaghan, Stephen A. Goutman, Eva L. Feldman
First published June 1, 2016, DOI: https://doi.org/10.1212/NXI.0000000000000242
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1534

Share

Article Figures & Data

Figures

  • Figure 1.
    Figure 1. Immune cell populations are altered in the peripheral blood of patients with ALS

    (A) The total number of leukocytes and (B) the percent and total number of specific leukocyte populations are shown. Filled black circles represent individual healthy human control patients, and empty circles represent patients with ALS. Average and SEM are displayed. Asterisks above bars indicate significance (% of CD45+ cells: *p < 0.01, ***p < 0.0001; # of leukocytes: *p < 0.008). ALS = amyotrophic lateral sclerosis.

  • Figure 2.
    Figure 2. Percentage of CD16− monocytes in the blood is reduced during disease progression

    The percentage and total number of leukocytes in the blood of patients with amyotrophic lateral sclerosis are correlated with their ALSFRS-R score at the time of blood draw. Data are displayed with best-fit line and 95% confidence intervals. R2 value and p value are also shown. ALSFRS-R scores are displayed from high (A) to low (B) to illustrate disease progression. ALSFRS-R = Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised.

  • Figure 3.
    Figure 3. Percentage and total number of CD16− monocytes expressing CCR3 is reduced in patients with ALS

    The percentage and total number of CD16+ and CD16− monocytes expressing CCRL2 (A) and CCR3 (B) in the peripheral blood are shown. Filled black circles represent individual healthy human control patients, and empty circles represent patients with ALS. Average and SEM are displayed. Asterisks above bars indicate significance (*p < 0.025). ALS = amyotrophic lateral sclerosis.

  • Figure 4.
    Figure 4. The N:M ratio is significantly increased in patients with ALS and correlates with disease progression

    (A) The N:M ratio in healthy control patients (filled black circles) and patients with ALS (empty circles) is shown. Average and SEM are displayed. Asterisks above bars indicate significance (***p < 0.001). (B) The N:M ratio in the blood of patients with ALS is correlated with the ALSFRS-R score at the time of blood draw. Data are displayed with best-fit line and 95% confidence intervals. R2 value and p value are also shown. ALSFRS-R scores are displayed from high (left) to low (right) to illustrate disease progression. ALS = amyotrophic lateral sclerosis; ALSFRS-R = ALS Functional Rating Scale–Revised; N:M ratio = neutrophil to CD16− monocyte ratio.

Additional Files

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me

Recommended articles